Bioceltix（BCX）株式概要Bioceltix S.A.は、幹細胞ベースの動物用バイオ医薬品の開発に従事している。 詳細BCX ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( PLN0 )現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るBCX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValuezłCurrent Pricezł82.60165.2m% 割高 内在価値ディスカウントEst. Revenue$PastFuture-15m982016201920222025202620282031Revenue zł97.9Earnings zł17.8AdvancedSet Fair ValueView all narrativesBioceltix S.A. 競合他社BIOTONSymbol: WSE:BIOMarket cap: zł371.4mCaptor Therapeutics Spolka AkcyjnaSymbol: WSE:CTXMarket cap: zł495.6mSynthaverseSymbol: WSE:SVEMarket cap: zł207.4mMabionSymbol: WSE:MABMarket cap: zł117.3m価格と性能株価の高値、安値、推移の概要Bioceltix過去の株価現在の株価zł82.6052週高値zł116.8052週安値zł70.00ベータ1.011ヶ月の変化-0.36%3ヶ月変化2.61%1年変化-28.17%3年間の変化17.66%5年間の変化n/aIPOからの変化136.00%最新ニュースNew Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years).New Risk • Mar 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł368.4m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years). Market cap is less than US$100m (zł368.4m market cap, or US$99.5m).分析記事 • Dec 11We Think Bioceltix (WSE:BCX) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...New Risk • Sep 15New major risk - Revenue and earnings growthEarnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m.お知らせ • Aug 27Bioceltix S.A. to Report First Half, 2025 Results on Sep 30, 2025Bioceltix S.A. announced that they will report first half, 2025 results on Sep 30, 2025New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (zł6.5m net loss next year). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding).最新情報をもっと見るRecent updatesNew Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years).New Risk • Mar 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł368.4m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years). Market cap is less than US$100m (zł368.4m market cap, or US$99.5m).分析記事 • Dec 11We Think Bioceltix (WSE:BCX) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...New Risk • Sep 15New major risk - Revenue and earnings growthEarnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m.お知らせ • Aug 27Bioceltix S.A. to Report First Half, 2025 Results on Sep 30, 2025Bioceltix S.A. announced that they will report first half, 2025 results on Sep 30, 2025New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (zł6.5m net loss next year). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding).お知らせ • May 21Bioceltix S.A., Annual General Meeting, Jun 16, 2025Bioceltix S.A., Annual General Meeting, Jun 16, 2025.分析記事 • Mar 05We're Not Very Worried About Bioceltix's (WSE:BCX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (zł356.5m market cap, or US$90.4m).New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (zł312.7m market cap, or US$79.2m).分析記事 • Jun 15We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Jun 01Bioceltix S.A., Annual General Meeting, Jun 26, 2024Bioceltix S.A., Annual General Meeting, Jun 26, 2024, at 11:00 Central European Standard Time.お知らせ • Jan 24+ 3 more updatesBioceltix S.A. to Report Fiscal Year 2023 Results on Apr 26, 2024Bioceltix S.A. announced that they will report fiscal year 2023 results on Apr 26, 2024分析記事 • Jan 19Will Bioceltix (WSE:BCX) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Sep 21We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Jun 02Bioceltix S.A., Annual General Meeting, Jun 27, 2023Bioceltix S.A., Annual General Meeting, Jun 27, 2023, at 12:00 Central European Standard Time.分析記事 • May 09We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, Bioceltix ( WSE:BCX...お知らせ • Jan 12+ 3 more updatesBioceltix S.A. to Report Q3, 2023 Results on Nov 21, 2023Bioceltix S.A. announced that they will report Q3, 2023 results on Nov 21, 2023お知らせ • Sep 10Bioceltix S.A. to Report First Half, 2022 Results on Sep 27, 2022Bioceltix S.A. announced that they will report first half, 2022 results on Sep 27, 2022お知らせ • Jul 19Bioceltix S.A. announced that it expects to receive PLN 4.21608 million in fundingBioceltix S.A. announced a private placement of 140,536 common shares at the price of KRW 1,310 per share for gross proceeds of 4.21608 million on July 18, 2022.お知らせ • May 21Bioceltix S.A., Annual General Meeting, Jun 15, 2022Bioceltix S.A., Annual General Meeting, Jun 15, 2022, at 12:00 Central European Standard Time.株主還元BCXPL BiotechsPL 市場7D-0.8%-0.4%3.1%1Y-28.2%-10.4%27.8%株主還元を見る業界別リターン: BCX過去 1 年間で-10.4 % の収益を上げたPolish Biotechs業界を下回りました。リターン対市場: BCXは、過去 1 年間で27.8 % のリターンを上げたPolish市場を下回りました。価格変動Is BCX's price volatile compared to industry and market?BCX volatilityBCX Average Weekly Movement5.5%Biotechs Industry Average Movement5.4%Market Average Movement5.3%10% most volatile stocks in PL Market11.0%10% least volatile stocks in PL Market3.2%安定した株価: BCX 、 Polish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: BCXの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201641Lukasz Bzdzionbioceltix.comBioceltix S.A.は、幹細胞ベースの動物用バイオ医薬品の開発に従事している。同社の製品には、犬の変性関節病変の治療のための幹細胞ベースの生物学的薬剤BCX-CM-J、犬のアトピー性皮膚炎の治療のための同種幹細胞ベースの生物学的薬剤候補BCX-CM-AD、馬の関節炎の治療のための同種間葉系幹細胞ベースの生物学的薬剤候補BCX-EMが含まれる。同社は2018年に法人化され、ポーランドのヴロツワフを拠点としている。もっと見るBioceltix S.A. 基礎のまとめBioceltix の収益と売上を時価総額と比較するとどうか。BCX 基礎統計学時価総額zł406.76m収益（TTM）-zł15.19m売上高(TTM)n/a0.0xP/Sレシオ-26.8xPER（株価収益率BCX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BCX 損益計算書（TTM）収益zł0売上原価zł0売上総利益zł0その他の費用zł15.19m収益-zł15.19m直近の収益報告Dec 31, 2025次回決算日May 29, 2026一株当たり利益（EPS）-3.08グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%BCX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 01:25終値2026/05/26 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioceltix S.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Beata Szparaga-WasniewskaBiuro maklerskie mBanku
New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years).
New Risk • Mar 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł368.4m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years). Market cap is less than US$100m (zł368.4m market cap, or US$99.5m).
分析記事 • Dec 11We Think Bioceltix (WSE:BCX) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
New Risk • Sep 15New major risk - Revenue and earnings growthEarnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m.
お知らせ • Aug 27Bioceltix S.A. to Report First Half, 2025 Results on Sep 30, 2025Bioceltix S.A. announced that they will report first half, 2025 results on Sep 30, 2025
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (zł6.5m net loss next year). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding).
New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years).
New Risk • Mar 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł368.4m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years). Market cap is less than US$100m (zł368.4m market cap, or US$99.5m).
分析記事 • Dec 11We Think Bioceltix (WSE:BCX) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
New Risk • Sep 15New major risk - Revenue and earnings growthEarnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m.
お知らせ • Aug 27Bioceltix S.A. to Report First Half, 2025 Results on Sep 30, 2025Bioceltix S.A. announced that they will report first half, 2025 results on Sep 30, 2025
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (zł6.5m net loss next year). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding).
お知らせ • May 21Bioceltix S.A., Annual General Meeting, Jun 16, 2025Bioceltix S.A., Annual General Meeting, Jun 16, 2025.
分析記事 • Mar 05We're Not Very Worried About Bioceltix's (WSE:BCX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (zł356.5m market cap, or US$90.4m).
New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (zł312.7m market cap, or US$79.2m).
分析記事 • Jun 15We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Jun 01Bioceltix S.A., Annual General Meeting, Jun 26, 2024Bioceltix S.A., Annual General Meeting, Jun 26, 2024, at 11:00 Central European Standard Time.
お知らせ • Jan 24+ 3 more updatesBioceltix S.A. to Report Fiscal Year 2023 Results on Apr 26, 2024Bioceltix S.A. announced that they will report fiscal year 2023 results on Apr 26, 2024
分析記事 • Jan 19Will Bioceltix (WSE:BCX) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Sep 21We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Jun 02Bioceltix S.A., Annual General Meeting, Jun 27, 2023Bioceltix S.A., Annual General Meeting, Jun 27, 2023, at 12:00 Central European Standard Time.
分析記事 • May 09We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, Bioceltix ( WSE:BCX...
お知らせ • Jan 12+ 3 more updatesBioceltix S.A. to Report Q3, 2023 Results on Nov 21, 2023Bioceltix S.A. announced that they will report Q3, 2023 results on Nov 21, 2023
お知らせ • Sep 10Bioceltix S.A. to Report First Half, 2022 Results on Sep 27, 2022Bioceltix S.A. announced that they will report first half, 2022 results on Sep 27, 2022
お知らせ • Jul 19Bioceltix S.A. announced that it expects to receive PLN 4.21608 million in fundingBioceltix S.A. announced a private placement of 140,536 common shares at the price of KRW 1,310 per share for gross proceeds of 4.21608 million on July 18, 2022.
お知らせ • May 21Bioceltix S.A., Annual General Meeting, Jun 15, 2022Bioceltix S.A., Annual General Meeting, Jun 15, 2022, at 12:00 Central European Standard Time.
